Ultragenyx Pharmaceutical (RARE)
(Real Time Quote from BATS)
$51.76 USD
0.00 (0.00%)
Updated Aug 15, 2024 10:06 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 281 - 300 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The KRN23 BLA for Adults and Pediatric XLH Patients Expected in August; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Bone Fracture Data is Positive for KRN23 Program, But Challenges Remain with Overall Profile, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Best News May Be Done for Some TIme, Downgrading to Neutral, New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Reducing PT: Adult XLH Results Support KRN23 Approval, but Less Robust Pain Benefit Likely to Slow Uptake
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
KRN23 Phase 3 Results Expected 1H17 Which We Expect to Be Positive; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Glut1 DS Seizure Study Failure Raises Risk for UX007, Reiterate OP but Reducing PT to $80 as We Revise our Outlook for Program.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage with an OUTPERFORM Rating and $88PT; Multiple Catalysts for RARE in 2017 as Late-Stage Pipeline Advances to Registration
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
UX007 Lowers Event Rate in Patients with LC-FAOD - Focus on Phase III Design; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2016 World Orphan Drug Congress Recap: Emerging Trends in Rare Disease Therapeutics
Provider: Rodman & Renshaw, Co.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
In Line with Our Expectations, Ace-ER Approval Will Require Phase III Data; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
After the Election: Impact to Biotech of a Trump Presidency
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
KRN23 Pediatric XLH BLA Filing Confirmed for 2H17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Updates on All Fronts as Ultragenyx Reports 3Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Updating Price Target to $109; Increased Confidence in KRN23 Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C